Gravitas
Previously known as LTNhell63
- Joined
- Jan 29, 2026
- Posts
- 5,324
- Reputation
- 14,851
What is erdafitinib?
-Erdafitinib, also sold under the brand name Balversa is a targeted cancer medication used as an oral tablet, it belongs to a class of medications called kinase inhibitors.
It is specifically prescribed for patients whose cancer has progressed after previous treatments and carries susceptible FGFR3 genetic alterations.
-Is a pan-FGFR inhibitor, it binds to and blocks the enzymatic activity of FGFR1-4
The lower the IC50, the stronger the FGFR inhibition.
What are FGFRs?
FGFRs (Fibroblast Growth Factor Receptors) are a family of four proteins. They regulate cell growth, division, and tissue development. When these genes mutate or malfunction, they can cause skeletal disorders or drive the uncontrolled growth of various types of cancer.
FGFR3 is a height growth limiter
So here's the question: if FGFR3 limits height, could erdafitinib help you grow taller by inhibiting it?
Let's take a look at some studies:
Patient 1
Patient 1 was diagnosed with a mesencephalic glioma grade II-III at 5 years of age,
Bioptic reevaluation at local progression in the brainstem at age 12 years revealed a low-grade tumor with an FGFR1 alteration, off-label treatment with erdafitinib was initiated at 13.8 years
The initial erdafitinib dose of 5 mg/day had to be paused and lowered to 3 mg/d for bone pain and abdominal aches
after 6 months of erdafitinib revealed a dramatic growth spurt!
Wrist imaging revealed an atypical physeal widening without apparent progression of bone maturation
Testosterone was initiated to advance pubertal development and induce growth plate fusion
Patient 2
Patient 2 was diagnosed with an FGFR3-overexpressing ependymoma at 4 years of age. There was no alteration of the endocrine function of therapeutic relevance. After standard therapy with irradiation and chemotherapy, she suffered from recurrences and tumor progression. Treatment was switched to erdafitinib at 10.9 years of age.
With onset of treatment with erdafitinib, there was an unanticipated growth spurt despite previous growth retardation.
Low IGF-1, suggesting Erda works independently of the hormonal system yet the growth velocity increased at nearly 4 times.
Erdafitinib can entail dangerous consequences when administered without the appropriate premedications, however, it has been shown to induce rapid growth acceleration in certain individuals.
Unfortunately, we lack growth studies of Erda in healthy individuals
This should be a brief introduction to erdafitinib and what it can do. Please consult a healthcare professional before starting any treatment.
Thanks for reading this
-LTNhell
@HtnceI @incelincel @Panchitosbroncs @motionmantris
-Erdafitinib, also sold under the brand name Balversa is a targeted cancer medication used as an oral tablet, it belongs to a class of medications called kinase inhibitors.
It is specifically prescribed for patients whose cancer has progressed after previous treatments and carries susceptible FGFR3 genetic alterations.
-Is a pan-FGFR inhibitor, it binds to and blocks the enzymatic activity of FGFR1-4
| Receptor | IC50 (nmol/L) |
|---|---|
| FGFR1 | 1.2 |
| FGFR2 | 2.5 |
| FGFR3 | 3 |
| FGFR4 | 5.7 |
The lower the IC50, the stronger the FGFR inhibition.
What are FGFRs?
FGFRs (Fibroblast Growth Factor Receptors) are a family of four proteins. They regulate cell growth, division, and tissue development. When these genes mutate or malfunction, they can cause skeletal disorders or drive the uncontrolled growth of various types of cancer.
| Receptor | Role |
|---|---|
| FGFR1 | Bone and tooth formation, Phosphate metabolism |
| FGFR2 | Organ and tissue formation |
| FGFR3 | Limits bone growth and growth plate activity |
| FGFR4 | Bile acid regulation, lipid and glucose metabolism, muscle regeneration. |
FGFR3 is a height growth limiter
So here's the question: if FGFR3 limits height, could erdafitinib help you grow taller by inhibiting it?
Let's take a look at some studies:
Patient 1
Patient 1 was diagnosed with a mesencephalic glioma grade II-III at 5 years of age,
Bioptic reevaluation at local progression in the brainstem at age 12 years revealed a low-grade tumor with an FGFR1 alteration, off-label treatment with erdafitinib was initiated at 13.8 years
The initial erdafitinib dose of 5 mg/day had to be paused and lowered to 3 mg/d for bone pain and abdominal aches
after 6 months of erdafitinib revealed a dramatic growth spurt!
Wrist imaging revealed an atypical physeal widening without apparent progression of bone maturation
Testosterone was initiated to advance pubertal development and induce growth plate fusion
Patient 2
Patient 2 was diagnosed with an FGFR3-overexpressing ependymoma at 4 years of age. There was no alteration of the endocrine function of therapeutic relevance. After standard therapy with irradiation and chemotherapy, she suffered from recurrences and tumor progression. Treatment was switched to erdafitinib at 10.9 years of age.
With onset of treatment with erdafitinib, there was an unanticipated growth spurt despite previous growth retardation.
Low IGF-1, suggesting Erda works independently of the hormonal system yet the growth velocity increased at nearly 4 times.
Erdafitinib can entail dangerous consequences when administered without the appropriate premedications, however, it has been shown to induce rapid growth acceleration in certain individuals.
Unfortunately, we lack growth studies of Erda in healthy individuals
This should be a brief introduction to erdafitinib and what it can do. Please consult a healthcare professional before starting any treatment.
Thanks for reading this
-LTNhell
@HtnceI @incelincel @Panchitosbroncs @motionmantris
